Funding Opportunities

The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.

Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding.
 

Notice of Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Program Official
Biology of Bladder Cancer PAR-22-218 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 09/08/2025
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes PAR-22-131 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 09/08/2025 Richard Mazurchuk, Ph.D.
Notice of Special Interest (NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases NOT-DA-22-048 01/08/2026 Sharon Ross, Ph.D., M.P.H.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-23-313 (UH2/UH3 Clinical Trial Not Allowed) UH2, UH3 Clinical Trial Not Allowed 10/15/2026 Sudhir Srivastava, Ph.D., M.P.H.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-23-314 (UH3 Clinical Trials Not Allowed) UH3 10/15/2026 Sudhir Srivastava, Ph.D., M.P.H.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers PAR-23-286 (K99/R00 - Independent Clinical Trial Not Allowed) R00, K99 Clinical Trial Not Allowed 10/15/2026 Jessica Faupel-Badger, Ph.D., M.P.H.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers PAR-23-287 (K99/R00 - Independent Clinical Trial Required) R00, K99 Clinical Trial Required 10/15/2026 Jessica Faupel-Badger, Ph.D., M.P.H.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers PAR-23-288 (K99/R00 - Independent Basic Experimental Studies with Humans Required) R00, K99 10/15/2026 Jessica Faupel-Badger, Ph.D., M.P.H.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics PAR-23-279 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 01/08/2027 Edward Sauter, M.D., Ph.D.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics PAR-23-280 (R21 Clinical Trial Not Allowed) R21 Clinical Trial Not Allowed 01/08/2027 Edward Sauter, M.D., Ph.D.